EP3377616A1 - Verfahren zur herstellung von haarfollikeln und de novo papillen sowie deren verwendung für in vitro tests und in vivo implantate - Google Patents
Verfahren zur herstellung von haarfollikeln und de novo papillen sowie deren verwendung für in vitro tests und in vivo implantateInfo
- Publication number
- EP3377616A1 EP3377616A1 EP16797504.4A EP16797504A EP3377616A1 EP 3377616 A1 EP3377616 A1 EP 3377616A1 EP 16797504 A EP16797504 A EP 16797504A EP 3377616 A1 EP3377616 A1 EP 3377616A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- hair
- ctsf
- novo
- dpf
- papilla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
- C12N5/0627—Hair cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
- C12N5/0698—Skin equivalents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1323—Adult fibroblasts
Definitions
- the object of the present invention is to reduce or avoid one or more disadvantages of the prior art.
- the present invention achieves this object by providing a method for producing de novo papillae, comprising the steps of: a) providing isolated papilla fibroblasts (DPF) from at least one hair papilla (DP, abbreviation for English dermal papilla ) from at least one hair follicle; b) providing isolated connective tissue fibroblasts (CTSF,
- de novo papillae can be prepared from mixtures of at least DPF and CTSF.
- Manufacturing process can be performed in a shorter time compared to known in the art for the duplication of hair follicles. Accordingly, it is possible within a day to gain cell populations from hair follicles, using these cells to produce de novo papillae and / or hair follicles in a larger number and to implement these newly generated de novo papillae or hair follicles into the hairless scalp to be treated, thus new hair can be formed again in these places.
- the method according to the invention relates to the production of de novo papillae.
- de novo papilla neopapilla
- spheroid are used interchangeably to refer to a substantially spheroidal cell aggregate of hair papillary fibroblasts (DPF) and connective tissue fibroblasts (CTSF)
- the de novo papilla thus comprises a mixture of at least DPF and CTSF.
- the de novo papillae consist of approximately 2 to 20,000 cells, preferably 10 to 15,000, more preferably 500 to 10,000, most preferably 1,000 to 5,000 cells.
- the de novo papilla has at least half the size of a physiological hair papilla (DP
- DP physiological hair papilla
- the de novo papilla also preferably has the approximate shape of a physiological DP of a hair follicle after isolation thereof.
- the de novo papilla may comprise a coating which includes one or more
- the de novo papilla contains different extracellular matrix proteins such as collagen IV, fibronectin and / or laminin. This coating can be created by the DPF and CTSF themselves while they form the de novo papilla. Alternatively or additionally, the de novo papilla may also be coated during and / or after its formation by the additional addition of one or more different extracellular matrix proteins to the culture medium.
- the production method of the present invention is carried out in vitro.
- in vitro is meant any environment that is not within a living organism, eg, a human or animal body
- detection method explicitly does not include a method which is performed on the human or animal body.
- isolated hair papillary fibroblasts (DPF) from at least one hair papilla (DP) are provided in a first method step a), the DP originating from at least one hair follicle.
- the provision of the DP from the hair follicle and the isolation of the DPF from the DP can be carried out, for example, as follows: Isolated hair follicles are e.g. fixed with tweezers on the hair shaft and the connective tissue sheath is e.g. with another pair of tweezers diametrically separated from the hair shaft, so that the bulbus is everted and thus exposed the DPF and the hair shaft with the hair matrix. This allows the DP to be separated from the remainder of the hair follicle, e.g. can be done with the help of a needle or cannula.
- the isolated DP are for example transferred to a cell culture vessel and fixed mechanically on the surface of the cell culture vessel.
- the DPF are obtained by mechanically arresting the isolated DP at the bottom of the cell culture vessel, e.g. using a needle point or a scalpel.
- the morphology of the DP remains approximately the same, but the basal lamina of the DP is slightly perforated so that the DPF can migrate out of the DP.
- the DPF can also be obtained by enzymatic or non-enzymatic separation from the DP.
- the DPF may be cultured after their isolation and before their use in the process according to the invention, for example in order to duplicate them. Accordingly, the DPF used in the process according to the invention can be descendants or clones of the originally isolated DPF.
- the hair follicles from which the DP and DPF are isolated originate from tissue.
- the hair follicles are removed from the tissue according to standards of good medical practice.
- the removal of hair follicles from the tissue is such that they are substantially intact, i. undamaged, stay.
- the removal of the hair follicles from the tissue can be carried out, for example, as follows: i) separation of the
- Epidermis of the underlying dermis or fatty tissue preferably using a scalpel; ii) preparation of hair from the dermis or the
- the extracted hairs include the hair follicles at their proximal end.
- the dermis or fatty tissue can be compressed so that the hair follicles present therein can be more easily removed.
- the compression can be carried out for example with the help of tweezers.
- the removal of the hair follicles takes place under the microscope.
- the hair follicles are obtained from punch biopsies, which consist of preferably individual follicular units (FE).
- FE follicular unit
- a follicular unit is the name given to a group of 1 to 4 hair follicles that grow in close proximity to each other
- the tissue capsule is surrounded and moved by a common muscle (M. arrector pilli).
- the follicular units are either recovered by dissection under one
- the latter method is called
- FUE Follicular Unit Extraction
- the tissue from which the hair follicles can be obtained from a mammal.
- This mammal may be a human, monkey, pig, dog, cat or rodent, preferably a human.
- the mammal is a donor to the tissue containing the hair follicle. More preferably, the mammal is a human patient suffering from hair loss.
- the tissue preferably comprises skin. This can make the tissue of each hairy
- Body region are preferably obtained from the head, chest, eyebrows, beard,
- the tissue is removed from a body region located near the body site affected by hair loss.
- the tissue can preferably be removed from the neck or temporal region of the head.
- the tissue is obtained by biopsy.
- this tissue Before the hair follicles, e.g. the isolation of the DP or DPF, are removed from the tissue, this tissue can be subjected to one or more purification steps to remove any interfering substances from the tissue.
- step b) of the method according to the invention isolated connective tissue fibroblasts (CTSF) are provided from at least one hair follicle.
- CSF connective tissue fibroblasts
- the provision of the CTSF from the hair follicle can be carried out, for example, as follows: Isolated hair follicles are fixed with tweezers on the hair shaft, for example, and the connective tissue sheath is separated diametrically from the hair shaft with another tweezers so that the bulbus is everted. This allows the proximal part of the bulb to be separated from the rest of the hair follicle with the CTSF, which can be done using a needle or cannula, for example. Subsequently, the isolated connective tissue sheath is transferred, for example, into a cell culture vessel and fixed mechanically on the surface of the cell culture vessel.
- the CTSF are obtained by mechanically arresting the isolated connective tissue sheath at the bottom of the cell culture vessel, eg by means of a needle tip or a needle tip
- the morphology of the connective tissue sheath is approximately preserved, but the connective tissue is slightly perforated so that the CTSF can migrate from the connective tissue.
- the CTSF may also be obtained by enzymatic or non-enzymatic separation from the connective tissue.
- the CTSF may be cultured after their isolation and before their use in the process according to the invention, for example to duplicate them. Accordingly, the CTSF used in the process according to the invention may be descendants or clones of the originally isolated CTSF.
- the hair follicles from which the CTSF is isolated originate from tissue.
- the hair follicles are removed from the tissue according to standards of good medical practice.
- the removal of hair follicles from the tissue is such that they are substantially intact, i. undamaged, stay.
- Removal of the hair follicles from the tissue can, for example, be carried out as follows: i) removal of the epidermis from the underlying dermis or fatty tissue, preferably using a scalpel; ii) preparation of hair from the dermis or the fatty tissue of the tissue.
- the extracted hairs include the hair follicles at their proximal end.
- the dermis or fatty tissue can be compressed so that the hair follicles present therein can be more easily removed.
- the compression can be carried out for example with the help of tweezers.
- the removal of the hair follicles takes place under the microscope.
- the tissue from which the hair follicles comes from a mammal.
- This mammal may be a human, monkey, pig, dog, cat or rodent, preferably a human.
- the mammal is a donor to the tissue containing the hair follicle. More preferably, the mammal is a human patient suffering from hair loss.
- the tissue preferably comprises skin.
- the tissue can be obtained from any hairy body region, preferably from the head, chest, eyebrows, beard, genital area, leg or other body regions. More preferably, the tissue is removed from a body region located near the body site affected by hair loss. For example, hair loss affects the head, so the between the forehead and the back of the head located part of the head, so the tissue may preferably be removed from the neck or temple area of the head.
- the tissue is obtained by biopsy.
- this tissue Before the hair follicles, e.g. the isolation of the CTSF from the tissue, this tissue may be subjected to one or more purification steps to remove any interfering substances present from the tissue.
- the DPF and CTSF are thus obtained from isolated hair follicles.
- the DPF and CTSF can be obtained from the same hair follicle.
- the DPF and CTSF can also be obtained from different hair follicles. If the DPF and CTSF are obtained from different hair follicles, these hair follicles may have been isolated from the same tissue, for example from a tissue which is e.g. was taken from the neck area of the head of a donor. If the DPF and CTSF are obtained from different hair follicles, then these hair follicles may have been isolated from various tissues, such that, for example, one of the tissues is e.g. was taken from the neck area of the head of a donor and the other tissue e.g. from the beard of a donor.
- the donor may be the same donor or donor. If it is another donor, this is preferably an allogeneic donor. Preferably, it is the same, so autologous, donor.
- step c) of the process according to the invention the co-cultivation of the DPF and CTSF takes place under essentially non-adherent cell culture conditions for the formation of spheroidal cell aggregates.
- non-adherent cell culture conditions means cell culture conditions in which the cells have essentially no direct and / or lasting contact with the surface of the cell
- Cell culture vessel have. This can be achieved, for example, in that the surfaces of the cell culture vessel consist of a material and / or have an anti-adhesion coating, which reduces or attaches the cell attachment
- Suitable culture vessels and / or coatings for these cell culture vessels are known to the person skilled in the art.
- Such non-adherent cell culture vessels can be made of glass or polystyrene, for example.
- the surfaces of the cell culture vessel are coated with contact-inhibiting materials such as PTFE, polyHEMA, agarose or fluorocarbon solutions.
- the definition of the non-adherent cell culture conditions also includes the so-called cultivation method of the "hanging drop"("Hanging).
- the surface tension of the liquid keeps the drop in a hanging position on the surface of the cell culture vessel and encloses the cells inside it Part of the drop and essentially have no direct contact with the culture vessel. Within the drop, the cells can form into spheroids.
- the DPF and CTSF can be co-cultured in the same or different ratio.
- the DPF and CTSF are co-cultured in a ratio of 1-20: 1-20, preferably 1-10: 1-10, more preferably 1-5: 1-5, most preferably 1-2.5: 1 -2.5, particularly preferably 1: 1.
- a cell concentration of 2 to 20,000 DPF + CTSF / mm 2 of the cell culture vessel is selected for co-cultivation of the DPF and CTSF in step c), preferably 10 to 15,000, more preferably 500 to 10,000, most preferably 1,000 to 5,000 ,
- the cell culture vessels may be, for example, commercially available cell culture plates, dishes or bottles.
- the cell culture vessels may have one or more cavities.
- the co-cultivation of the DPF and CTSF preferably takes place in a well of a cell culture vessel.
- the cell culture vessels may be so-called multiwell plates with more than one cavity.
- the cell culture vessels preferably have 2 to 10,000 cavities, particularly preferably 4 to 1536, very particularly preferably 6 to 384.
- the bottoms of the cell culture vessel cavities may be flat or uneven.
- the cavity bottoms are formed as a round arch. Also preferred are cavities which are funnel-shaped.
- the DPF and CTSF are sedimented by centrifugation at the bottom of the cell culture vessels prior to their co-cultivation in step c). This initial concentration of the DPF and CTSF at the bottom of the cell culture vessel results in faster cell aggregation.
- the co-cultivation of the DPF and CTSF takes place for at least 1 min, preferably for 10 min to 14 days, particularly preferably for 20 min to 48 h, very particularly preferably for 30 min to 24 h, particularly preferably for 1 h to 4 h.
- the co-cultivation of the DPF and CTSF preferably takes place in step c) of the method according to the invention in the presence of blood plasma and / or blood serum.
- the blood plasma and / or blood serum are human blood plasma and / or blood serum, preferably autologous blood plasma and / or blood serum.
- the blood plasma and / or blood serum is 1 to 100% blood plasma or blood serum, preferably 15 to 75%, particularly preferably 30 to 50% pure.
- the co-cultivation of the DPF and CTSF in step c) of the process according to the invention can take place under essentially static conditions or with agitation.
- step c) of the method according to the invention additional cell types may additionally be present.
- endothelial cells (EZ) and / or cells of stromal vascular fractions (SVF) are additionally present during co-culture.
- the EZ can be obtained from blood vessels, preferably from blood vessels, which are on or in
- the DC are obtained from a human donor.
- This is particularly preferably autologous DC.
- development cooperation may take place after its isolation and prior to its use in the
- the DCs used in the method according to the invention may be descendants or clones of the originally isolated DC.
- the presence of EZ in the cocultivation of the DPF with the CTSF in step c) of the method according to the invention produces de novo papillae comprising DPF, CTSF and EZ.
- Such de novo papillae, or hair follicles generated from them can be incorporated into the skin of a mammal for the treatment of a reduced amount of hair.
- Such de novo papillae or hair follicles generated from them allow accelerated formation of the skin after transplantation into the skin
- the SVF can be obtained for example by means of fatty tissue excision or liposuction.
- the SVF is obtained from a human donor, more preferably is an autologous SVF.
- the SVFs include various Cell populations such as precursors of fat cells (pre-adipocytes), endothelial cells, endothelial muscle cells, fibroblasts, macrophages or blood cells.
- pre-adipocytes precursors of fat cells
- endothelial cells endothelial cells
- endothelial muscle cells fibroblasts
- macrophages or blood cells.
- certain components of the SVF may be removed from the SVF after they have been recovered from the donor, which may be accomplished by one or more wash, sanitize, or
- Isolation steps can be done or by targeted separation or removal of the ingredients. It is also possible that the SVF be cultured after their isolation and before their use in the process according to the invention, for example, to reproduce them. Accordingly, the SVF used in the process according to the invention can be descendants or clones of the originally isolated SVF.
- the presence of the SVF in the co-cultivation in step c) of the method according to the invention results in an increased or faster cell multiplication of the DPF and CTSF and correspondingly accelerates the formation of the de novo papillae.
- the other cell types may be present in the same or different ratio to the DPF and CTSF.
- the DPF, CTSF and EZ or SVF are co-cultured in a ratio of 1 -20: 1 -20: 1 -20, preferably 1 -10: 1 -10: 1 -10, particularly preferably 1 -5: 1 - 5: 1 -5, very particularly preferably 1 -2.5: 1 -2.5: 1 -2.5, particularly preferably 1: 1: 1.
- the co-cultivation is preferably carried out in a ratio of 1 -20: 1 -20: 1 -20: 1 -20, preferably 1 -10: 1 -10: 1. 10: 1-10, more preferably 1-5: 1-5: 1-5, most preferably 1-2.5: 1- 2.5: 1-2.5: 1-2.5 , more preferably 1: 1: 1: 1.
- a layer of extracellular matrix proteins usually forms in and / or around the cell aggregate, which is usually formed by the DPF and / or CTSF.
- This can for example be achieved by e.g. a composition comprising these extracellular matrix proteins in addition to the culture medium is added in order to facilitate and / or accelerate the formation of this papillae coating.
- the de novo papilla separates first from the culture medium and then with a
- compositions comprising these extracellular matrix proteins are added.
- This composition of the extracellular matrix proteins added preferably comprises collagen IV, fibronectin and / or laminin.
- this composition comprises or consists of the additionally added extracellular matrix proteins collagen IV, fibronectin and laminin, preferably in a ratio of 2-6: 0.5-2: 0.5-2 parts by weight, more preferably in a ratio of 3-5: 0.5-1, 5: 0.5-1, 5 parts by weight, most preferably in a ratio of 4: 1: 1, 15 parts by weight.
- the Composition of the extracellular matrix proteins can also be used in combination with other matrices.
- the extracellular matrix protein composition further comprises other collagens (such as collagen I, collagen 10A1, collagen 18A1), glycosaminoglycans and / or proteoglycans, preferably
- the de novo papilla is coated by adding extracellular matrix proteins into the cell culture medium with these matrix proteins.
- the coating of the de novo papilla with the extracellular matrix proteins preferably also takes place in the
- Substantially non-adherent cell culture conditions take place.
- the coating of the de novo papilla takes place for at least 1 min, preferably for 10 min to 14 days, particularly preferably for 20 min to 48 h, very particularly preferably for 30 min to 24 h, particularly preferably for 1 h to 4 h.
- the present invention also relates to de novo papillae, which are produced by the method according to the invention.
- the method of making de novo papillae comprises the steps of: a) providing isolated DPF from at least one DP from at least one hair follicle; b) providing CTSF from at least one hair follicle; and c) co-culturing the DPF and CTSF and additionally EZ under essentially non-adherent cell culture conditions to form spheroidal cell aggregates.
- the DPF, CTSF and EZ are cocultivated in a ratio of 1 -20: 1 -20: 1 -20.
- the de novo papillae are preferably coated by addition of extracellular matrix proteins into the cell culture medium with these matrix proteins.
- the co-cultivation can take place under rotation, pivoting or shaking movements.
- the co-cultivation may preferably take place in a cylindrical cavity, which preferably has a round bottom. It is possible to carry out the co-cultivation in multiwell cell culture vessels with, for example, 96 or 384 wells.
- the co-cultivation may take place in the presence of blood plasma and / or blood serum.
- the DPF, CTSF and EZ are from a donor.
- the method for producing de novo papillae comprises the steps: a) providing isolated DPF from at least one DP from at least one hair follicle; b) providing CTSF from at least one hair follicle; and c) co-culturing the DPF and CTSF and additionally SVF under substantially non-adherent cell culture conditions to form spheroidal cell aggregates.
- the DPF, CTSF and SVF are in a ratio of 1 -20: 1 -20: 1 -20 co- cultured.
- the de novo papillae are preferably coated with extracellular matrix proteins.
- the co-cultivation may take place under rotation, panning or shaking. Furthermore, the co-cultivation may take place in the presence of blood plasma and / or blood serum.
- the DPF, CTSF and SVF are from a donor.
- the method for producing de novo papillae comprises the steps: a) providing isolated DPF from at least one DP from at least one hair follicle; b) providing CTSF from at least one hair follicle; and c) co-culturing the DPF, CTSF and additionally EZ and SVF under substantially non-adherent cell culture conditions.
- the DPF, CTSF, EZ and SVF are co-cultured in a ratio of 1 -20: 1 -20: 1 -20: 1 -20.
- the de novo papillae are preferably coated with extracellular matrix proteins.
- the co-cultivation may take place under rotation, panning or shaking.
- co-culture may take place in the presence of blood plasma and / or blood serum.
- the DPF, CTSF, EZ and SVF are from a donor.
- the present invention relates to a method for producing hair follicles, comprising the steps of: a) providing at least one de novo papilla produced by the method according to the invention for the production of de novo papillae; b) providing at least one further cell population selected from keratinocytes (KC), melanocytes (MC) or connective tissue fibroblasts (CTSF); and c) co-culturing the de novo papilla with the at least one other cell population under substantially non-adherent cell culture conditions.
- KC keratinocytes
- MC melanocytes
- CTSF connective tissue fibroblasts
- the "hair follicle” produced by the method of the present invention refers to an incomplete follicular structure compared to natural hair follicles, which may comprise a condensed core (papilla) of fibroblasts of mesenchymal origin and an enveloping outer and / or inner epithelial hair root sheath but without other cell types or structures such as muscle or nerve cells, blood vessels, etc., so that the hair follicles have a reduced size compared to natural ones
- a hair follicle is composed of a de novo papilla of at least DPF and CTSF stable with at least one other cell population selected from keratinocytes (KC), melanocytes (MC) or fibroblasts, e.g. CTSF, covered or colonized.
- KC keratinocytes
- MC melanocytes
- fibroblasts e.g. CTSF
- a hair follicle is composed of a de novo papilla stable with at least one other cell population selected from KC,
- the MC or CTSF is covered or colonized, wherein the at least one further cell population can be obtained from a hair follicle or is recovered.
- the hair follicle has a three-dimensional, possibly spatially limited form, which the
- the Hair follicles may have a polar structure, such as a sharp bulge on one side of the hair follicle, reminiscent of structures of early morphogenesis of physiological hair follicles.
- At least one de novo papilla is provided in a first method step a), wherein the de novo papilla was produced by the method described above.
- step b) of the method according to the invention for producing the hair follicles at least one further cell population selected from KC, MC or CTSF is provided.
- step c) of the method according to the invention for producing the hair follicles the co-culture of the de novo papilla with the at least one further cell population selected from keratinocytes (KC), melanocytes (MC) or
- CTSF Connective tissue fibroblasts
- the KC, MC and / or CTSF do not have to be from one
- Hair follicles but may be derived from other mammalian tissues, e.g. Skin, to be won.
- the at least one further cell population can be obtained from a hair follicle and / or it is obtained from a hair follicle.
- the KC, MC and / or CTSF can be obtained from the same hair follicle.
- the KC, MC and / or CTSF can also be obtained from different hair follicles. If the KC, MC and / or CTSF are derived from different hair follicles, these hair follicles may have been isolated from the same tissue, for example from a tissue which is e.g. was taken from the neck area of the head of a donor. If the KC, MC and / or CTSF are derived from different hair follicles, these hair follicles may also have been isolated from different tissues such that, for example, one of the tissues is e.g.
- the donor was taken from the neck area of the head of a donor and another tissue e.g. from the beard of a donor.
- the donor may be the same donor or donor. If it is another donor, this is preferably an allogeneic donor. Preferably, it is the same, so autologous, donor.
- the at least one further cell population is obtained from the same hair follicle from which the DP has been isolated.
- inventive method for producing the hair follicles are cultured, for example, to duplicate them. Accordingly, it can be in the KC, MC and / or CTSF used by offspring or clones of the originally isolated KC, MC and / or CTSF act according to the invention.
- the at least one further cell population may be in the same or in one
- the de novo papilla is co-cultured with KC, MC and / or CTSF in a ratio of 1-10: 1-50, more preferably in a ratio of 1-5: 1-40.
- the de novo papilla is co-cultured with KC and MC, preferably in a ratio of 1-10: 1-50: 1-50, preferably in a ratio of 1-5: 1-20: 1-20.
- the de novo papilla is co-cultured with KC, MC and CTSF, preferably in a ratio of 1-10: 1-50: 1-50: 1-50.
- the co-cultivation of the de novo papilla with the KC and MC is preferably carried out first, so that the KC and MC form a layer around the de novo papilla, and then the co-cultivation with the CTSF.
- Sheath with CTSF hair follicles are formed with which improved
- the co-cultivation of the de novo papilla with the at least one further cell population takes place for at least 10 minutes, preferably for 20 minutes to 3 weeks, particularly preferably for 30 minutes to 24 hours, very particularly preferably for 1 hour to 4 hours.
- the co-cultivation of the de novo papilla with the at least one further cell population in step c) of the method according to the invention for producing the hair follicles can take place under substantially static conditions or with movement.
- the co-cultivation takes place under rotation, pivoting or shaking movements.
- Hair follicles the steps: a) providing at least one de novo papilla produced by the method according to the invention for the production of de novo papillae; b)
- the de novo papilla preferably comprises DPF, CTSF and additionally EZ and / or SVF.
- the de novo papilla is preferably coated with extracellular matrix proteins.
- the de novo papilla, KC and MC are co-cultured in a ratio of 1-10: 1-50: 1-50.
- the co-cultivation can take place under rotation, pivoting or shaking movements.
- the co-cultivation may preferably take place in a cylindrical cavity, which preferably has a round bottom.
- both the cells for the production of the de novo papilla, as well as the KC and MC come from a donor.
- the method for the production of hair follicles comprises the steps: a) provision of at least one de novo papilla prepared by the method according to the invention for the production of de novo papillae; b)
- the de novo papilla preferably comprises DPF, CTSF and additionally EZ and / or SVF.
- the de novo papilla is preferably coated with extracellular matrix proteins.
- the de novo papilla, KC, MC and CTSF are co-cultured in a ratio of 1 -10: 1 -50: 1 -50: 1 -50.
- the co-cultivation may take place under rotation, panning or shaking.
- the co-cultivation may preferably take place in a cylindrical cavity, which preferably has a round bottom.
- both the cells for the production of the de novo papilla, as well as the KC, MC and the CTSF originate from a donor.
- the present invention also includes hair follicles produced by the
- the de novo papillae and / or the hair follicles produced by one of the methods of the present invention can be used for the preparation of a skin equivalent.
- the skin equivalents are prepared on the basis of a skin matrix, wherein the skin matrix is, for example, an artificial dermal matrix, such as e.g. Matriderm® or a donor skin. Become into this skin matrix
- Insertion sites for example in the form of perforations, for the de novo introduced papillae and / or hair follicles, for example by means of a punch, scalpel or laser. These insertion sites may be introduced into the skin matrix at regular or irregular intervals.
- the de novo papillae and / or hair follicles are inserted into the insertion sites of the dermal matrix.
- the present invention also relates to a skin equivalent comprising the de novo papilla and / or the hair follicles produced by one of the methods of the invention.
- the skin equivalent may additionally comprise one or more layers of KC and / or MC, which layer (s) are preferably applied via the de novo papillae and / or hair follicles located in the dermal matrix.
- the skin equivalent may include other cells and / or cell structures such as immune cells (dendritic cells, lymphocytes, etc.), neuronal cells, sebaceous and sweat gland cells / tissues, muscle cells / fibers, vascular structures and other cell types contained in natural, healthy or diseased skin are.
- the de novo papillae and / or hair follicles produced by one of the methods of the invention may be used for the manufacture of an implant. Accordingly, the present invention also relates to an implant comprising the de novo papillae and / or the hair follicles produced by one of the methods of the invention, optionally together with pharmaceutically tolerable ones
- the present invention also relates to the use of the de novo papilla, the hair follicles produced by the method according to the invention and / or the skin equivalent comprising the de novo papillae and / or hair follicles for the
- allogeneic cells be used for the production of the de novo papillae and / or hair follicles, which means that the donor of the cells used and the recipient of the de novo papillae and / or hair follicles produced are the same Belong to species, ie that both donor and recipient are, for example, humans.
- autologous cells be used for the production of the de novo papillae and / or hair follicles, which means that the donor of the cells used and the recipient of the de novo papillae produced and / or Hair follicle is identical, ie, for example, is the same human.
- the present invention also relates to the use of the de novo papilla, hair follicles and / or skin equivalents according to the invention for the in vitro testing of hair growth-regulating substances.
- the present invention also relates to the use of the de novo papilla, hair follicles and / or skin equivalents according to the invention for the in vitro testing of substances for toxic properties.
- the present invention also includes a kit for carrying out the invention
- the kit can be the de novo papillae according to the invention
- Hair follicle, the skin equivalent, the implant and / or the graft for example, the inventive method for treating a condition of reduced
- Kit also includes instructions for using the kit and / or performing it of the inventive method. Furthermore, the kit may contain further constituents for carrying out the method according to the invention, such as, for example
- Reaction vessels Reaction vessels, filters, solutions and / or other means.
- the present invention comprises a method for treating a
- the present invention also relates to a method for in vitro screening of substances having hair growth-regulating properties, comprising the following steps: a) providing a sample of the de novo papilla according to the invention,
- Hair follicles and / or skin equivalents b) dividing the corresponding sample into portions; c) incubate at least one portion of substances to be tested; and d) comparing the parameters of the hair properties in the portion with another portion that was not incubated with the substances
- Figures Figure 1 shows:
- FIG. 2 shows:
- the FU consists essentially of the hair shaft, the epidermis, dermis, sebaceous gland, connective tissue sheath (CTSF), root sheaths (ORS, IRS, KC), sweat gland, blood vessels (endothelial cells), pigment unit (melanocytes), dermal papilla (DPF) and adipose tissue (adipocytes, SVF).
- FIG. 3 shows:
- DP de novo papilla
- KC epithelial
- the hair shaft which also contains the hair matrix keratinocytes and melanocytes required, is optimally prepared for further cultivation.
- Hair follicles are each collected in a separate vessel with medium.
- tissue dissociator and the associated Extractions kit eg gentleMACS Dissociator # 130-093-235, whole skin dissociation kit # 130-101 -540, Miltenyi Biotec
- the DPF and CTSF are removed from the tissue and separated , For this purpose, each of the isolated tissue fragments
- the sample is incubated in a 37 ° C water bath for 1 to 3 hours or overnight, with longer incubation times increasing cell yield. After incubation, dilute the sample by adding 0.5 ml of cold cell culture medium. The C-Tube is closed and fastened inverted on the sleeve of the gentleMACS Dissociator.
- WPF stromal vascular fraction
- the corresponding area with head or beard hair is washed and disinfected (70% ethanol) and each 20-30 hair plucked with a rubber-coated tweezers. Only the hair with an adherent layer of tissue is transferred to a vessel and rinsed in PBS. Subsequently, the hairs are incubated in 2 ml trypsin / EDTA solution at 37 ° C for 20 minutes and then mixed briefly with a shaker. The enzyme reaction is stopped with 4 ml trypsin inhibitor. Wash with PBS and centrifuge the suspension at 200g for 5 minutes. The cells can then be taken up in medium and used for further culture or after cell counting for further in vitro hair follicle preparation.
- Round bottom Multiwell plate (Corning) pipetted (in DMEM + 10% FCS and DermaLife medium in a ratio of 1: 1) or mixed beforehand with cells of the SVF or endothelial cells and then transferred into the wells of the multiwell plate. This will last for 2 min at 200g centrifuged and incubated under rotation at 20 rounds per minute for 20 min at room temperature. For the longer culture daily medium is changed.
- a mixture of melanocytes and keratinocytes resulting from tissue dissociation from isolated or plucked hair shafts are taken up in cell culture medium and pipetted in each case to the de novo papillae (15,000
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102015119880.0A DE102015119880B4 (de) | 2015-11-17 | 2015-11-17 | Verfahren zur Herstellung von Haarfollikeln und de novo Papillen sowie deren Verwendung für in vitro Tests und in vivo Implantate |
PCT/EP2016/077541 WO2017084999A1 (de) | 2015-11-17 | 2016-11-14 | Verfahren zur herstellung von haarfollikeln und de novo papillen sowie deren verwendung für in vitro tests und in vivo implantate |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3377616A1 true EP3377616A1 (de) | 2018-09-26 |
Family
ID=57326372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16797504.4A Pending EP3377616A1 (de) | 2015-11-17 | 2016-11-14 | Verfahren zur herstellung von haarfollikeln und de novo papillen sowie deren verwendung für in vitro tests und in vivo implantate |
Country Status (7)
Country | Link |
---|---|
US (1) | US11174463B2 (de) |
EP (1) | EP3377616A1 (de) |
JP (2) | JP2018533960A (de) |
CN (1) | CN108473951A (de) |
AU (1) | AU2016357986A1 (de) |
DE (1) | DE102015119880B4 (de) |
WO (1) | WO2017084999A1 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3072972B1 (fr) * | 2017-10-30 | 2023-03-10 | Oreal | Procede de preparation in vitro d’equivalents de papille dermique et de follicule pileux |
JP7246595B2 (ja) * | 2018-11-08 | 2023-03-28 | 国立大学法人横浜国立大学 | 毛包原基、毛包原基の製造方法、及び毛包原基に含まれる細胞の活性化方法 |
EP3992273A4 (de) * | 2019-06-28 | 2023-10-18 | Riken | Kulturbehälter und verfahren zur herstellung von regenerativen haarfollikelkeimen mit dem kulturbehälter |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL143243A0 (en) * | 1998-11-19 | 2002-04-21 | Organogenesis Inc | A cultured tissue construct containing fibroblast cells and methods for the production thereof |
US20030161815A1 (en) * | 2002-02-12 | 2003-08-28 | Intercytex Limited | Cell delivery system |
KR100616752B1 (ko) * | 2004-11-29 | 2006-08-31 | 박정극 | 모낭 유도 능력이 있는 모유두 조직의 제조방법 |
JP5227024B2 (ja) * | 2005-09-30 | 2013-07-03 | 株式会社フェニックスバイオ | 毛包真皮毛根鞘細胞の培養法 |
WO2007100870A2 (en) | 2006-02-28 | 2007-09-07 | The Trustees Of Columbia University In The City Of New York | Methods for compact aggregation of dermal cells |
EP2105499A1 (de) | 2008-03-28 | 2009-09-30 | Technische Universität Berlin | Verfahren zum Herstellen von Novo Papillae und Haarmikrofollikeln und ihre Verwendung bei In-vitro-Tests und in-vivo-Implantationen |
US20110305671A1 (en) * | 2010-06-10 | 2011-12-15 | Alvi Armani Genomics Inc. | Cell Compositions and Methods for Hair Follicle Generation |
IN2013MN00607A (de) * | 2010-09-29 | 2015-09-11 | Shiseido Co Ltd | |
PL2635299T3 (pl) * | 2010-11-02 | 2020-03-31 | The Trustees Of Columbia University In The City Of New York | Sposoby leczenia zaburzeń utraty włosów |
FR2976001B1 (fr) * | 2011-05-30 | 2014-10-31 | Oreal | Modele de cuir chevelu reconstruit et procede de screening de molecules actives |
US20160136206A1 (en) * | 2013-06-18 | 2016-05-19 | Replicel Life Sciences Inc. | Compositions and methods for treating skin |
-
2015
- 2015-11-17 DE DE102015119880.0A patent/DE102015119880B4/de active Active
-
2016
- 2016-11-14 JP JP2018525687A patent/JP2018533960A/ja active Pending
- 2016-11-14 US US15/776,359 patent/US11174463B2/en active Active
- 2016-11-14 AU AU2016357986A patent/AU2016357986A1/en not_active Abandoned
- 2016-11-14 CN CN201680078151.6A patent/CN108473951A/zh active Pending
- 2016-11-14 WO PCT/EP2016/077541 patent/WO2017084999A1/de active Application Filing
- 2016-11-14 EP EP16797504.4A patent/EP3377616A1/de active Pending
-
2021
- 2021-11-19 JP JP2021188693A patent/JP7370613B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
US20200255799A1 (en) | 2020-08-13 |
DE102015119880B4 (de) | 2018-05-24 |
CN108473951A (zh) | 2018-08-31 |
DE102015119880A1 (de) | 2017-05-18 |
WO2017084999A1 (de) | 2017-05-26 |
US11174463B2 (en) | 2021-11-16 |
AU2016357986A1 (en) | 2018-06-21 |
JP7370613B2 (ja) | 2023-10-30 |
JP2022031757A (ja) | 2022-02-22 |
JP2018533960A (ja) | 2018-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1509597B1 (de) | Verfahren zur Isolierung von mesenchymalen Stammzellen des Haarfollikels | |
AU2011268139B2 (en) | Hair follicle neogenesis | |
US7419661B2 (en) | Dermal sheath tissue in wound healing | |
EP3146973B1 (de) | Haarwachstumsfördernde funktion von kleinen stammzellen und verwendung davon | |
JP7370613B2 (ja) | 毛包およびデノボ乳頭の作製方法ならびにインビトロ試験およびインビボ移植のためのそれらの使用 | |
US8617882B2 (en) | Skin-derived precursor cells and uses thereof | |
Wu et al. | Hair follicle reformation induced by dermal papilla cells from human scalp skin | |
DE69820254T2 (de) | Dermales hüllgewebe in der wundheilung | |
DE69824017T2 (de) | Vehikel zur gentherapie enthaltend dermales huellgewebe | |
EP2209463B1 (de) | Verfahren zum erhöhen der pigmentierung von haut unter verwendung von melanozytenvorläuferzellen | |
EP3377124B1 (de) | Verfahren zur herstellung eines hautäquivalents sowie dessen verwendung für in vitro tests und in vivo transplantate | |
CN110520137A (zh) | 用于头皮或皮肤的改质、创伤治愈或毛发的改质的药物组合物 | |
EP2354220B1 (de) | Verfahren zur Herstellung einer mesenchymalen Stammzellenpräparation | |
Yun et al. | Construction of Nude Mouse Skin and Hair Follicle by Modified Chamber Assay |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180615 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20210318 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |